Piramal Pharma Stock Gains 2% On US FDA Clearance
Successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to our high-end analytical capabilities to customers
The stocks of Piramal Pharma rose over 2 per cent in the Monday trading session after the successful closure of US FDA Inspection at Piramal Pharma’s manufacturing facility located at Ahmedabad.
Piramal Pharma stock traded at Rs 153 with 1.82 per cent gain in the morning session on the National Stock Exchange (NSE).
“This is to inform you that the US FDA conducted a Pre-Approval Inspection (PAI) of
Piramal Pharma Limited's PPDS Ahmedabad facility from 10 July 2024 to 12 July 2024. The inspection was completed successfully with Zero Form - 483 observations and no action indicated (NAI) designation,” stated Piramal Pharma in an exchange filing.
The company further stated that, successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to our high-end analytical capabilities to our customers for their clinical and commercial batches from an FDA approved site.
Piramal Pharma also ensured its commitment to maintain the highest standards of compliance.
In terms of stock performance, Piramal Pharma stock delivered merely a return of nearly 11 per cent in 2024 so far. Whereas, the benchmark index, Nifty Pharma more than 23 per cent year-to-date (YTD).
 (1)_20240712174244_original_image_10.webp)
